31,389 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Purchased by Guggenheim Capital LLC

Guggenheim Capital LLC purchased a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 31,389 shares of the company's stock, valued at approximately $807,000.

Several other large investors also recently added to or reduced their stakes in IDYA. XTX Topco Ltd increased its holdings in IDEAYA Biosciences by 64.3% in the 4th quarter. XTX Topco Ltd now owns 12,679 shares of the company's stock worth $326,000 after acquiring an additional 4,960 shares in the last quarter. Mariner LLC boosted its holdings in shares of IDEAYA Biosciences by 9.8% during the 4th quarter. Mariner LLC now owns 9,775 shares of the company's stock valued at $251,000 after purchasing an additional 869 shares during the last quarter. Barclays PLC increased its stake in IDEAYA Biosciences by 9.7% in the 4th quarter. Barclays PLC now owns 198,756 shares of the company's stock worth $5,108,000 after acquiring an additional 17,586 shares during the last quarter. Raymond James Financial Inc. bought a new stake in IDEAYA Biosciences in the fourth quarter worth $431,000. Finally, Renaissance Technologies LLC raised its position in shares of IDEAYA Biosciences by 66.9% during the 4th quarter. Renaissance Technologies LLC now owns 284,267 shares of the company's stock valued at $7,306,000 after buying an additional 113,902 shares in the last quarter. 98.29% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on IDYA. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Royal Bank of Canada reiterated an "outperform" rating and set a $61.00 target price on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Finally, Stephens reaffirmed an "overweight" rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IDEAYA Biosciences has an average rating of "Moderate Buy" and an average price target of $53.58.

IDEAYA Biosciences Trading Down 0.4 %

Shares of NASDAQ:IDYA traded down $0.07 on Friday, hitting $19.00. 1,686,295 shares of the company were exchanged, compared to its average volume of 954,813. The stock's 50 day moving average price is $18.00 and its 200 day moving average price is $23.46. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $44.42. The firm has a market capitalization of $1.66 billion, a P/E ratio of -5.76 and a beta of 0.51.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82). The firm had revenue of $7.00 million during the quarter, compared to analyst estimates of $7.00 million. On average, equities analysts predict that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.